A Multi-center, Multi-dose Phase Ib/IIa Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy, Pharmacokinetics, and Impact on Biomarkers of IPG11406 in Patients with Lupus Nephritis
Latest Information Update: 12 Feb 2025
Price :
$35 *
At a glance
- Drugs IPG 11406 (Primary)
- Indications Lupus nephritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Immunophage Biotech
- 10 Feb 2025 Planned initiation date changed from 31 Dec 2024 to 20 Feb 2025.
- 10 Feb 2025 Status changed from not yet recruiting to recruiting.
- 10 Dec 2024 New trial record